Do we need controlled clinical trials in pulmonary arterial hypertension?

被引：14

作者：

Galiè, N ^{[1
]}

机构：

[1] Univ Bologna, Ist Cardiol, I-40138 Bologna, Italy

来源：

EUROPEAN RESPIRATORY JOURNAL | 2001年 / 17卷 / 01期

关键词：

D O I：

10.1183/09031936.01.17100010

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

引用

页码：1 / 3

页数：3

共 22 条

[1] Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease -: A randomized, controlled trial [J].

Badesch, DB ;

Tapson, VF ;

McGoon, MD ;

Brundage, BH ;

Rubin, LJ ;

Wigley, FM ;

Rich, S ;

Barst, RJ ;

Barrett, PS ;

Kral, KM ;

Jöbsis, MM ;

Loyd, JE ;

Murali, S ;

Frost, A ;

Girgis, R ;

Bourge, RC ;

Ralph, DD ;

Elliott, CG ;

Hill, NS ;

Langleben, D ;

Schilz, RJ ;

McLaughlin, VV ;

Robbins, IM ;

Groves, BM ;

Shapiro, S ;

Medsger, TA ;

Gaine, SP ;

Horn, E ;

Decker, JC ;

Knobil, K .

ANNALS OF INTERNAL MEDICINE, 2000, 132 (06) :425-+

[2] A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [J].

Barst, RJ ;

Rubin, LJ ;

Long, WA ;

McGoon, MD ;

Rich, S ;

Badesch, DB ;

Groves, BM ;

Tapson, VF ;

Bourge, RC ;

Brundage, BH ;

Koerner, SK ;

Langleben, D ;

Keller, CA ;

Murali, S ;

Uretsky, BF ;

Clayton, LM ;

Jobsis, MM ;

Blackburn, SD ;

Shortino, D ;

Crow, JW .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :296-301

[3] AN IMBALANCE BETWEEN THE EXCRETION OF THROMBOXANE AND PROSTACYCLIN METABOLITES IN PULMONARY-HYPERTENSION [J].

CHRISTMAN, BW ;

MCPHERSON, CD ;

NEWMAN, JH ;

KING, GA ;

BERNARD, GR ;

GROVES, BM ;

LOYD, JE .

NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (02) :70-75

[4] FIBRINOPEPTIDE-A LEVELS INDICATIVE OF PULMONARY VASCULAR THROMBOSIS IN PATIENTS WITH PRIMARY PULMONARY-HYPERTENSION [J].

EISENBERG, PR ;

LUCORE, C ;

KAUFMAN, L ;

SOBEL, BE ;

JAFFE, AS ;

RICH, S .

CIRCULATION, 1990, 82 (03) :841-847

[5] The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension [J].

Frank, H ;

Mlczoch, J ;

Huber, K ;

Schuster, E ;

Gurtner, HP ;

Kneussl, M .

CHEST, 1997, 112 (03) :714-721

[6] Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension [J].

Friedman, R ;

Mears, JG ;

Barst, RJ .

CIRCULATION, 1997, 96 (09) :2782-2784

[7] PRIMARY PULMONARY-HYPERTENSION - NATURAL-HISTORY AND THE IMPORTANCE OF THROMBOSIS [J].

FUSTER, V ;

STEELE, PM ;

EDWARDS, WD ;

GERSH, BJ ;

MCGOON, MD ;

FRYE, RL .

CIRCULATION, 1984, 70 (04) :580-587

[8] ROLE OF PHARMACOLOGICAL TESTS IN THE TREATMENT OF PRIMARY PULMONARY-HYPERTENSION [J].

GALIE, N ;

USSIA, G ;

PASSARELLI, P ;

PARLANGELI, R ;

BRANZI, A ;

MAGNANI, B .

AMERICAN JOURNAL OF CARDIOLOGY, 1995, 75 (03) :A55-A62

[9] Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. [J].

Hoeper, MM ;

Schwarze, M ;

Ehlerding, S ;

Adler-Schuermeyer, A ;

Spiekerkoetter, E ;

Niedermeyer, J ;

Hamm, M ;

Fabel, H .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (25) :1866-1870

[10]

Klings ES, 1999, ARTHRITIS RHEUM, V42, P2638, DOI 10.1002/1529-0131(199912)42:12<2638::AID-ANR20>3.0.CO

← 1 2 3 →